In 1984 was created DEFTA Partners, which is appeared as VC. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the San Francisco.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the DEFTA Partners, startups are often financed by Hatteras Venture Partners, 180 Degree Capital, Walden Venture Capital. The meaningful sponsors for the fund in investment in the same round are Walden Venture Capital, LabCorp, Hatteras Venture Partners. In the next rounds fund is usually obtained by Walden Venture Capital, Spectrum Health Ventures, Redpoint.
The overall number of key employees were 3.
Considering the real fund results, this VC is 4 percentage points less often commits exit comparing to other organizations. The higher amount of exits for fund were in 2009. The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2019. This DEFTA Partners works on 3 percentage points less the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline ORIG3N, Intraspect Software, BIoEclipse Therapeutics The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular fund investment industries, there are Video, Blockchain.
Related Funds
Funds with similar focus
Fund Name | Location |
62 Capital | Australia, Nedlands, Western Australia |
D-Ax Corporate Venture Capital | Stockholm, Stockholm County, Sweden |
GENESIS Ventures | - |
Hua Ventures | China, Fujian, Futian |
LF Investment | - |
Magnetic Fund | - |
Maven Ventures | California, Palo Alto, United States |
Michael Grabner Media GmbH | Austria, Vienna |
Mizrahi Tefahot Bank | Israel, Tel Aviv, Tel Aviv District |
Ningbo Zeshi Touzi Guanli Co., Ltd | China, Ningbo, Zhejiang |
Nishikawa Associates | Japan, Kanagawa Prefecture, Kawasaki |
Protean Energy Advisors, LLC | - |
RenaissanceRe Holdings | Bermuda, Hamilton |
Scenic Investments | - |
Synchrony Bio | Missouri, Saint Louis, United States |
Tenacious Ventures | Australia, Melbourne, Victoria |
Tony muscarella | - |
Ying Fund | California, Los Angeles, United States |
Zero Point Holding | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Endogena Therapeutics | $21M | 13 Dec 2021 | San Francisco, California, United States | ||
InformAI | $1M | 01 May 2021 | Houston, Texas, United States | ||
Acepodia | $47M | 16 Mar 2021 | Vallejo, California, United States | ||
Endogena Therapeutics | $8M | 28 Jan 2021 | San Francisco, California, United States | ||
Aegle Therapeutics | $6M | 29 Sep 2020 | Miami, Florida, United States | ||
InformAI | $1M | 26 Jun 2020 | Houston, Texas, United States | ||
TARA Biosystems | $10M | 23 Jun 2020 | New York, New York, United States | ||
1World Online | $8M | 21 Feb 2020 | Redwood City, California, United States | ||
Aegle Therapeutics | $4M | 09 Jan 2020 | Miami, Florida, United States |
– Israel-based AI healthtech company, DiA Imaging Analysis, which is using deep learning and machine learning to automate analysis of ultrasound scans, has closed a $14m Series B round of funding.
– Backers in the growth round, which comes three years after DiA last raised, include new investors Alchimia Ventures, Downing Ventures, ICON Fund, Philips and XTX Ventures — with existing investors also participating, including CE Ventures, Connecticut Innovations, Defta Partners, Mindset Ventures, and Dr Shmuel Cabilly.
– The latest financing will allow DiA to continue expanding its product range and go after new and expanded partnerships with ultrasound vendors, PACS/Healthcare IT companies, resellers and distributors while continuing to build out its presence across three regional markets.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Endogena Therapeutics | $21M | 13 Dec 2021 | San Francisco, California, United States | ||
InformAI | $1M | 01 May 2021 | Houston, Texas, United States | ||
Acepodia | $47M | 16 Mar 2021 | Vallejo, California, United States | ||
Endogena Therapeutics | $8M | 28 Jan 2021 | San Francisco, California, United States | ||
Aegle Therapeutics | $6M | 29 Sep 2020 | Miami, Florida, United States | ||
InformAI | $1M | 26 Jun 2020 | Houston, Texas, United States | ||
TARA Biosystems | $10M | 23 Jun 2020 | New York, New York, United States | ||
1World Online | $8M | 21 Feb 2020 | Redwood City, California, United States | ||
Aegle Therapeutics | $4M | 09 Jan 2020 | Miami, Florida, United States |